ALTSHULER DAVID 4

What Happened

• David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals (VRTX), was issued a total of 11,194 earned performance shares on 01/22/2026. The filing shows two awards: 7,866 shares (price $0.00) and 3,328 shares (price $0.00), reflecting earned performance-stock-unit awards rather than purchases or sales. No cash was paid for these shares.

Key Details

• Transaction date reported: 2026-01-22; Form 4 filed: 2026-01-26 (filed within standard reporting window).
• Award details:
  • 7,866 shares: earned from a PSU grant originally dated 02/01/2023; committee certified performance on 01/22/2026; these shares vest on 02/13/2026. (Footnote F1)
  • 3,328 shares: earned from a PSU grant originally dated 02/12/2025; committee certified performance on 01/22/2026; these shares vest in installments beginning 02/24/2026. (Footnote F2)
• Transaction code: A (award/grant).
• Acquisition price reported: $0.00 per share; total reported cash value = $0.
• Shares owned after the transaction: not specified in the provided filing.

Context

• These were performance-vested awards (PSUs) that became payable after the company’s management development and compensation committee certified attainment of performance goals. This is compensatory issuance—not an insider purchase or sale—so it reflects earned compensation rather than a buy/sell signal.